GB:0G8X Stock Latest News
Company AnnouncementsImmunovia Reports Stronger PancreaSure Sales in Third Quarter5h ago
Company AnnouncementsImmunovia Sets Q3 2026 Report Release and Investor Webcast3d ago
Company AnnouncementsImmunovia Secures Shareholder Backing for Major Rights Issue and Capital Structure Changes4d ago
Company AnnouncementsImmunovia Sets Final Terms for Discounted Rights Issue to Fund PancreaSure Push4d ago
Company AnnouncementsImmunovia Builds Case for PancreaSure in Hereditary High-Risk Pancreatic Cancer Market4w ago
Company AnnouncementsImmunovia Launches SEK 63 Million Rights Issue to Fund PancreaSure Push1M ago
Company AnnouncementsImmunovia Survey Shows Strong Demand for Blood-Based Pancreatic Cancer Tests2M ago
Company AnnouncementsImmunovia AB Earnings Call: Early Traction, Funding Risks2M ago- Company AnnouncementsImmunovia boosts PancreaSure uptake as clinical evidence builds and cash burn stays below guidance2M ago
Company AnnouncementsImmunovia to Present Q2 2026 Report Amid Push in Pancreatic Cancer Diagnostics3M ago
Company AnnouncementsImmunovia Unveils New PancreaSure Data Ahead of Medicare Coverage Bid4M agoCompany AnnouncementsImmunovia’s PancreaSure Test Posts Strong Late-Stage Pancreatic Cancer Data in AFFIRM Study4M ago
Company AnnouncementsImmunovia Cuts Cash Burn as PancreaSure Expansion Nears Full U.S. Coverage5M ago- Company AnnouncementsImmunovia Cuts Cash Burn as PancreaSure U.S. Rollout Nears Nationwide Reach5M ago
Company AnnouncementsImmunovia Launches ASSURE Registry to Drive Real-World Adoption of PancreaSure6M ago- Company AnnouncementsImmunovia to Present Q1 2026 Results and Outline Strategic Objectives6M ago
Company AnnouncementsImmunovia Publishes 2025 Annual Report Focused on Pancreatic Cancer Diagnostics6M agoCompany AnnouncementsImmunovia Cuts Losses and Raises Capital as PancreaSure Gains U.S. Traction8M ago